OSI's PSN9301 reduces blood glucose levels in type 2 diabetes in phase 2a study

By Lisa Kerner

Charlotte, N.C., June 12 - OSI Pharmaceuticals said its phase 2a proof-of-concept study demonstrated that with-meal dosing, 14-day administration of its dipeptidyl peptidase-IV inhibitor PSN9301 reduced blood glucose levels in patients with type 2 diabetes.

In addition, PSN9301 was generally well tolerated with no episodes of hypoglycemia (low blood glucose).

"We believe that PSN9301's fast onset and short duration of action make it an ideal candidate for meal-related dosing, which will allow for optimal regulation of the glucose regulatory hormone GLP-1, the goal of intervention with DPIV [dipeptidyl peptidase-IV] inhibitors, while potentially reducing the risk of adverse effects between meals and overnight," president Anker Lundemose said in a company news release.

The phase 2a randomized, double-blind, placebo-controlled two-week in-clinic dosing trial explored the effects of several different doses of PSN9301 in 56 patients with type 2 diabetes.

In the three highest dose groups, (240 mg, 360 mg and 480 mg), the glucose area under the curve in response to an oral glucose tolerance test was reduced to 42% from 24% compared to a placebo.

The study results were presented at the annual meeting of the American Diabetes Association in Washington, D.C.

OSI develops pharmaceutical products for the treatment of cancer, eye diseases and diabetes.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.